Literature DB >> 28664408

Focal segmental glomerulosclerosis; why does it occur segmentally?

Michio Nagata1, Namiko Kobayashi2, Satoshi Hara3.   

Abstract

Podocyte loss is the fundamental basis of glomerulosclerosis. Focal segmental glomerulosclerosis (FSGS) is a progressive glomerular disease, and its glomerular features are a prototype of podocyte loss-driven glomerulosclerosis. The glomerular pathology of FSGS is characterized by a focal and segmental location of the sclerotic lesions in human FSGS; segmental sclerosis often shows simultaneous intra- and extra-capillary changes, including parietal cell migration, capillary collapse, hyaline deposition, and intra-capillary thrombi and occasional hypercellularity. This suggests that local cellular events, initiated by podocyte loss, are the basis of the segmental lesions in FSGS. Using podocyte-specific injury by toxin administration, a series of recent works has identified the cellular basis of the glomerular response to podocyte loss. This review discusses the molecular pathway of the local response to podocyte loss and its progression to sclerosis. Recent results suggest that segmental sclerosis is a physiological tissue response aimed at halting protein leakage from a disrupted filtration barrier.

Entities:  

Keywords:  Foam cells; Focal segmental glomerulosclerosis (FSGS); Microangiopathy; Parietal cells; Podocyte loss

Mesh:

Year:  2017        PMID: 28664408     DOI: 10.1007/s00424-017-2023-x

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  34 in total

1.  A hitherto undescribed vulnerability of the juxtamedullary glomeruli in lipoid nephrosis.

Authors:  A R RICH
Journal:  Bull Johns Hopkins Hosp       Date:  1957-04

Review 2.  Focal segmental glomerulosclerosis.

Authors:  Vivette D D'Agati; Frederick J Kaskel; Ronald J Falk
Journal:  N Engl J Med       Date:  2011-12-22       Impact factor: 91.245

3.  Glomerular damage after uninephrectomy in young rats. II. Mechanical stress on podocytes as a pathway to sclerosis.

Authors:  M Nagata; W Kriz
Journal:  Kidney Int       Date:  1992-07       Impact factor: 10.612

4.  Prevalence of CD44-positive glomerular parietal epithelial cells reflects podocyte injury in adriamycin nephropathy.

Authors:  Takayuki Okamoto; Satoshi Sasaki; Takeshi Yamazaki; Yasuyuki Sato; Hironobu Ito; Tadashi Ariga
Journal:  Nephron Exp Nephrol       Date:  2014-01-08

5.  Glomerular hypertrophy and epithelial cell injury modulate progressive glomerulosclerosis in the rat.

Authors:  J W Fries; D J Sandstrom; T W Meyer; H G Rennke
Journal:  Lab Invest       Date:  1989-02       Impact factor: 5.662

Review 6.  A potential role for mechanical forces in the detachment of podocytes and the progression of CKD.

Authors:  Wilhelm Kriz; Kevin V Lemley
Journal:  J Am Soc Nephrol       Date:  2014-07-24       Impact factor: 10.121

7.  Podocyte injury-driven intracapillary plasminogen activator inhibitor type 1 accelerates podocyte loss via uPAR-mediated β1-integrin endocytosis.

Authors:  Namiko Kobayashi; Toshiharu Ueno; Kumi Ohashi; Hanako Yamashita; Yukina Takahashi; Kazuo Sakamoto; Shun Manabe; Satoshi Hara; Yasutoshi Takashima; Takashi Dan; Ira Pastan; Toshio Miyata; Hidetake Kurihara; Taiji Matsusaka; Jochen Reiser; Michio Nagata
Journal:  Am J Physiol Renal Physiol       Date:  2015-01-13

8.  Tracer studies in the rat demonstrate misdirected filtration and peritubular filtrate spreading in nephrons with segmental glomerulosclerosis.

Authors:  Wilhelm Kriz; Ingrid Hartmann; Hiltraud Hosser; Brunhilde Hähnel; Bettina Kränzlin; Abaraham P Provoost; Norbert Gretz
Journal:  J Am Soc Nephrol       Date:  2001-03       Impact factor: 10.121

9.  Genetic podocyte lineage reveals progressive podocytopenia with parietal cell hyperplasia in a murine model of cellular/collapsing focal segmental glomerulosclerosis.

Authors:  Taisei Suzuki; Taiji Matsusaka; Makiko Nakayama; Takako Asano; Teruo Watanabe; Iekuni Ichikawa; Michio Nagata
Journal:  Am J Pathol       Date:  2009-04-09       Impact factor: 4.307

Review 10.  CD44 Acts as a Signaling Platform Controlling Tumor Progression and Metastasis.

Authors:  Véronique Orian-Rousseau
Journal:  Front Immunol       Date:  2015-04-08       Impact factor: 7.561

View more
  5 in total

1.  Clinical and pathological features of idiopathic membranous nephropathy with focal segmental sclerosis.

Authors:  Jiatong Li; Bing Chen; Caifeng Gao; Jing Huang; Yongmei Wang; Shiyin Zhang; Ying Xu; Wenkai Guo; Rong Wang
Journal:  BMC Nephrol       Date:  2019-12-16       Impact factor: 2.388

Review 2.  Molecular Mechanisms of Kidney Injury and Repair.

Authors:  Sandra Rayego-Mateos; Laura Marquez-Expósito; Raquel Rodrigues-Diez; Ana B Sanz; Roser Guiteras; Nuria Doladé; Irene Rubio-Soto; Anna Manonelles; Sergi Codina; Alberto Ortiz; Josep M Cruzado; Marta Ruiz-Ortega; Anna Sola
Journal:  Int J Mol Sci       Date:  2022-01-28       Impact factor: 5.923

3.  Parietal epithelial cells maintain the epithelial cell continuum forming Bowman's space in focal segmental glomerulosclerosis.

Authors:  Laura Miesen; Péter Bándi; Brigith Willemsen; Fieke Mooren; Thiago Strieder; Eva Boldrini; Vedran Drenic; Jennifer Eymael; Roy Wetzels; Johannes Lotz; Nick Weiss; Eric Steenbergen; Toin H van Kuppevelt; Merijn van Erp; Jeroen van der Laak; Nicole Endlich; Marcus J Moeller; Jack F M Wetzels; Jitske Jansen; Bart Smeets
Journal:  Dis Model Mech       Date:  2022-03-14       Impact factor: 5.758

Review 4.  Disease Recurrence-The Sword of Damocles in Kidney Transplantation for Primary Focal Segmental Glomerulosclerosis.

Authors:  Katrin Kienzl-Wagner; Siegfried Waldegger; Stefan Schneeberger
Journal:  Front Immunol       Date:  2019-07-17       Impact factor: 7.561

5.  A novel heterozygous variant of the COL4A4 gene in a Chinese family with hematuria and proteinuria leads to focal segmental glomerulosclerosis and chronic kidney disease.

Authors:  Liang-Liang Fan; Lv Liu; Fang-Mei Luo; Ran Du; Chen-Yu Wang; Yi Dong; Ji-Shi Liu
Journal:  Mol Genet Genomic Med       Date:  2020-11-07       Impact factor: 2.183

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.